Related Experiment Videos
CD44v6: a target for antibody-based cancer therapy
Karl-Heinz Heider1, Hartmut Kuthan, Gerd Stehle
1Boehringer Ingelheim Austria, Dr. Boehringer Gasse 5-11, 1121 Vienna, Austria. Karl-Heinz.Heider@vie.boehringer-ingelheim.com
Cancer Immunology, Immunotherapy : CII
|February 6, 2004
Summary
CD44 variant domain 6 (CD44v6) is highly expressed in many epithelial cancers but not normal tissues. This makes CD44v6 a promising target for antibody therapies against cancers like squamous cell carcinomas.
Area of Science:
- Molecular biology
- Immunology
- Oncology
Background:
- The CD44 gene encodes transmembrane glycoproteins crucial for cell interactions.
- Alternative splicing of CD44 exons generates diverse protein isoforms, including CD44 variant domain 6 (CD44v6).
- CD44v6 is linked to tumor development, invasion, and metastasis.
Purpose of the Study:
- To provide an overview of CD44v6 expression in human malignancies and normal tissues using immunohistochemistry.
- To review the clinical applications of CD44v6-specific antibodies.
- To assess CD44v6 as a therapeutic target in epithelial cancers.
Main Methods:
- Immunohistochemical analysis of CD44v6 expression.
- Review of clinical data on CD44v6-specific antibody applications.
- Comparison of CD44v6 expression in malignant versus nonmalignant tissues.
Main Results:
- CD44v6 expression is largely restricted to a subset of epithelia in nonmalignant tissues.
- Intense and homogeneous CD44v6 expression is prevalent in most squamous cell carcinomas and some adenocarcinomas.
- CD44v6 expression is infrequent in nonepithelial tumors.
Conclusions:
- The distinct expression pattern of CD44v6 in epithelial cancers versus normal tissues supports its role as a potential therapeutic target.
- CD44v6-specific antibodies show promise for targeted therapy in epithelium-derived cancers.
- Further clinical evaluation of CD44v6-targeted therapies is warranted.